Abstract
According to statistics, 81% of cases of COVID-19 coronavirus infection occur in a mild or moderate form. These patients make up the main part of the flow of calls to a general practitioner at the moment. The difficulties that therapists face during a pandemic are associated with finding the optimal therapy for the disease due to the gradual accumulation of knowledge about a new RNA-containing virus. The article presents the data of a study of the antiviral activity of the drug Lysobact Complete® in vitro on a Vero cell culture. Studies of previous years confirm the antiviral, anti-inflammatory, strengthening local immunity effect of lysozyme hydrochloride, the antiviral effect of cetylpyridinium chloride, both are the components of the drug Lysobact Complete® dosed spray for topical use. This in vitro study confirmed the antiviral activity of the drug on the SARS-CoV-2 virus, which makes its use promising in complex therapy of patients with COVID-19. The theoretical justification of the practical use of the drug is given. The authors hope that the research data will be useful to doctors when providing medical care to patients with COVID-19
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
